Bristol-Myers Squibb Co (NYSE:BMY)

49.46
Data as of Apr 17
 +0.35 / +0.71%
Today’s Change
39.18
Today|||52-Week Range
57.49
-6.94%
Year-to-Date
If This Biotech Drops Much Further I'm Going to Buy It!
Apr 17 / MotleyFool.com
UPDATE: Bristol-Myers Squibb Submits NDA to US FDA for Fixed-Dose Combo Tablet for At...
Apr 14 / Benzinga
Will Merck & Co. Inc Unseat Biotech's Hottest Drug?
Apr 17 / MotleyFool.com
Hedge Funds Love These 3 Pharma Stocks
Apr 14 / StreetAuthority
2 Reasons Why Merck & Co. Is Crushing the Dow
Apr 16 / MotleyFool.com
3 Stocks Reiterated As A Buy: BMY, LOW, CSCO
Apr 11 / TheStreet.com
Gilead Sciences, Inc. Feeling Sovaldi Pressure From All Sides
Apr 16 / MotleyFool.com
Encouraging Data from Bristol-Myers - Analyst Blog
Apr 11 / Zacks.com
Could This Small-Cap Biotech's Experimental Diabetes Drug Be a Game Changer?
Apr 16 / MotleyFool.com
Merck Shouts "Me, Too!" But Will It Matter?
Apr 11 / MotleyFool.com
3 Stocks Reiterated As A Buy: BMY, CELG, V
Apr 16 / TheStreet.com
Market Hustle: Stock Futures Sink as JPMorgan's Profit Shrinks
Apr 11 / TheStreet.com
Bristol-Myers Seeks Approval for HIV Combo Drug - Analyst Blog
Apr 15 / Zacks.com
Merck Up on Encouraging HCV Data - Analyst Blog
Apr 10 / Zacks.com
How Much Has Merck Shaken Up the Hepatitis C Race?
Apr 15 / MotleyFool.com
Stunning Spending Growth Prediction for Hepatitis C
Apr 10 / MotleyFool.com
Leaders Of The Pharmaceutical Pack
Apr 15 / StockTwits
Today's Biotech Stocks to Watch: Bristol-Myers Squibb, Gilead Sciences and Merck & Co...
Apr 10 / MotleyFool.com
Portola's Betrixaban Study Design Published - Analyst Blog
Apr 15 / Zacks.com
Oncolytics Reports Additional Data on Reolysin - Analyst Blog
Apr 09 / Zacks.com
This Forgotten Pharma Could Be a Hit for Your Portfolio
Apr 15 / MotleyFool.com
Positive Trial Data Lifts Alkermes - Analyst Blog
Apr 09 / Zacks.com
Can Merck & Co. Inc. and Bristol-Myers Squibb Co. Dethrone Gilead Sciences Inc. for H...
Apr 15 / MotleyFool.com
Bristol-Myers Seeks FDA Approval for HCV Candidates - Analyst Blog
Apr 08 / Zacks.com
Amgen's Conundrum
Apr 14 / MotleyFool.com
3 Under-Loved Dividend Darlings for Your Portfolio
Apr 04 / MotleyFool.com
Hard-to-Cure Patients May Benefit from Merck's HCV Drug - Analyst Blog
Apr 14 / Zacks.com
Forstmann Little eyes $2bn sale of 24 Hour Fitness chain
Apr 02 / FT.com
Positive Data on AbbVie's HCV Program - Analyst Blog
Apr 14 / Zacks.com
Bristol-Myers Squibb: side effects
Apr 01 / FT.com
Is This the Answer to Expensive Hepatitis-C Cures?
Apr 14 / MotleyFool.com
 

To view my watchlist

Not a member yet?

Sign up now for a free account
Market indexes are shown in real time, except for the DJIA, which is delayed by two minutes. All times are ET. Disclaimer LIBOR Warning: Neither BBA Enterprises Limited, nor the BBA LIBOR Contributor Banks, nor Reuters, can be held liable for any irregularity or inaccuracy of BBA LIBOR. Disclaimer. Morningstar: © 2014 Morningstar, Inc. All Rights Reserved. Disclaimer The Dow Jones IndexesSM are proprietary to and distributed by Dow Jones & Company, Inc. and have been licensed for use. All content of the Dow Jones IndexesSM © 2014 is proprietary to Dow Jones & Company, Inc. Chicago Mercantile Association. The market data is the property of Chicago Mercantile Exchange Inc. and its licensors. All rights reserved. FactSet Research Systems Inc. 2014. All rights reserved. Most stock quote data provided by BATS.